Observational studyImmunity, inflammation and disease2026
Efficacy of Dolutegravir Plus Lamivudine in People With TB/HIV Co-Infection Using a Rifampicin or Rifabutin-Based Regimen: A Retrospective Observational Case Series.
Observational study in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionCo-infection with tuberculosis (TB) is the leading cause of death in individuals infected with human immunodeficiency virus (HIV)-1. Dolutegravir and lamivudine (DTG + 3TC) has recently been recommended as the preferred first-line regimen for the treatment of new and treatment-experienced HIV-infected patients. The primary objective of this study was to determine the efficacy and safety of DTG (50 mg) + 3TC (300) mg in HIV-positive antiretroviral therapy (ART)-naïve patients with TB who received a rifampicin- or rifabutin-based treatment regimen and characterize viral suppression rates at week 48.
methodsA single-center retrospective observational case series, spanning January 1, 2021 to March 1, 2023, was conducted in Guiyang Public Health Treatment Center. Of 46 TB/HIV co-infected patients received DTG + 3TC or DTG/3TC, a total of 42 patients were finally enrolled in the study. The outcomes of interest were successful TB treatment, viral load (VL) suppression, and immunological and biochemical indexes.
resultsAll people with HIV infection (PWH) underwent at least 48 weeks of follow-up; all TB treatments were successful. A total of seven PWH (100%) achieved viral suppression (VL < 50 copies/mL) from a baseline VL greater than 500,000 copies/mL. Among the PWH who started DTG + 3TC after initiating the rifabutin-based anti-TB regimen, 31 (73.8%) achieved viral suppression by week 24. CD4 + T-cell counts were greatly improved after antiretroviral treatment. The CD4 + /CD8+ ratio increased by 0.38 (p < 0.001). Total cholesterol, and high-density lipoprotein cholesterol (p < 0.05). There were no significant changes in body mass index, low-density lipoprotein cholesterol, and triglyceride levels from baseline to week 48 (p > 0.05). No serious adverse events were observed.
conclusionThis case series preliminarily validated the efficacy of DTG + 3TC when combined with rifabutin-based anti-TB regimens in patients with TB and HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.